 DALLAS, March 02, 2022 GLOBE NEWSWIRE -- Instil Bio, Inc. Instil Nasdaq: TIL, a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that management will be participating in a Cell Therapy Panel at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 9:10 a.m. ET. 